JR-141
Phase 2Active 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Mucopolysaccharidosis II
Conditions
Mucopolysaccharidosis II
Trial Timeline
Jan 1, 2019 → Dec 31, 2027
NCT ID
NCT03708965About JR-141
JR-141 is a phase 2 stage product being developed by JCR Pharmaceuticals for Mucopolysaccharidosis II. The current trial status is active. This product is registered under clinical trial identifier NCT03708965. Target conditions include Mucopolysaccharidosis II.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05594992 | Phase 3 | Recruiting |
| NCT04348136 | Phase 2/3 | Active |
| NCT03708965 | Phase 2 | Active |
| NCT03568175 | Phase 2/3 | Completed |
| NCT03128593 | Phase 1/2 | Completed |
Competing Products
20 competing products in Mucopolysaccharidosis II